Rodolfo F Perini

Rodolfo F Perini

Central US Merck & Co., Inc. - / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4376402
person_outline Rodolfo F Perini's MOST POPULAR ARTICLES
1-) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma New England Journal of Medicine 380 (12), 1116-1127, 2019
2-) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma New England Journal of Medicine 384 (14), 1289-1300, 2021
3-) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase … The Lancet Oncology 18 (11), 1483-1492, 2017
4-) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma New England Journal of Medicine 385 (8), 683-694, 2021
5-) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinomaTK Choueiri, P Tomczak, SH Park, B Venugopal, T Ferguson, YH Chang, ...New England Journal of Medicine 385 (8), 683-694, 20216512021